Ling Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ling Lin has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Bei Wang
Department of Cardiology, Sanya Central Hospital (The Third People's Hospital of Hainan Province), Sanya, Hainan 572000, PR China
3 shared publicationsMichael J. Kutryk
Division of Cardiology, Keenan Research Center for Biomedical Science, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
2 shared publications- Nanshan Zhong
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
2 shared publications Qiuwang Zhang
Division of Cardiology, Keenan Research Center for Biomedical Science, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
2 shared publications- Zifeng Yang
Guangzhou National Laboratory
2 shared publications - Bei Wang
Sanya Central Hospital, Sanya, China
1 shared publication
Latest Publications
- Open Access
- 11 May 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1738410
The effect of DASH diet on components of metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials
Background: Metabolic syndrome (MetS) has emerged as an increasingly significant global health issue. The Dietary Approaches to Stop Hypertension (DASH) diet is recommended for managing MetS. However, existing meta-analyses often focus on individual MetS components, without providing a comprehensive evaluation of the DASH diet’s effects on the full spectrum of MetS components. Therefore, we conducted a systematic review and meta-analysis of randomized controlled trials evaluating the effects of the DASH diet on various components of MetS. Methods: We performed a comprehensive search of PubMed, Web of Science, Embase, and Cochrane Library databases, covering studies published until April 6, 2025. We included RCTs that evaluated the effects of the DASH diet on MetS components such as waist circumference (WC), blood pressure (BP), fasting blood glucose (FBG), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and Homeostasis Model Assessment-Insulin Resistance (HOMA-IR). Sensitivity analyses were conducted to assess result stability, and funnel plots were used to assess publication bias, with Egger’s test applied for significance ( p < 0.05). Additionally, we used the GRADE approach to assess the certainty of evidence. Results: A total of 14 studies involving 1,062 participants were included. The meta-analysis showed that, compared with non-DASH diets, the DASH diet significantly reduced WC (MD = −2.33 cm, 95% CI: −3.10 to −1.57), systolic BP (MD = −5.52 mmHg, 95% CI: −6.83 to −4.21), diastolic BP (MD = −3.93 mmHg, 95% CI: −4.76 to −3.10), TG (MD = −16.57 mg/dL, 95% CI: −23.53 to −9.61), HDL-C (MD = 1.44 mg/dL, 95% CI: 0.20 to 2.68), and HOMA-IR levels (MD = −0.71, 95% CI: −1.10 to −0.31). However, no significant difference was observed in FBG (MD = −0.91 mg/dL, 95% CI: −4.51 to 2.68). The GRADE approach for assessing certainty of evidence indicated that, with the exception of FBG and HDL-C where the certainty of evidence was low, the overall certainty of evidence for the remaining outcome measures was rated as moderate quality. Conclusion: The DASH diet appears to have a positive effect on components of MetS and can be considered an effective dietary intervention for MetS patients. Systematic review registration: CRD420251060235.
- 11 May 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1738410
Open AccessThe effect of DASH diet on components of metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials
Background: Metabolic syndrome (MetS) has emerged as an increasingly significant global health issue. The Dietary Approaches to Stop Hypertension (DASH) diet is recommended for managing MetS. However, existing meta-analyses often focus on individual MetS components, without providing a comprehensive evaluation of the DASH diet’s effects on the full spectrum of MetS components. Therefore, we conducted a systematic review and meta-analysis of randomized controlled trials evaluating the effects of the DASH diet on various components of MetS. Methods: We performed a comprehensive search of PubMed, Web of Science, Embase, and Cochrane Library databases, covering studies published until April 6, 2025. We included RCTs that evaluated the effects of the DASH diet on MetS components such as waist circumference (WC), blood pressure (BP), fasting blood glucose (FBG), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and Homeostasis Model Assessment-Insulin Resistance (HOMA-IR). Sensitivity analyses were conducted to assess result stability, and funnel plots were used to assess publication bias, with Egger’s test applied for significance ( p < 0.05). Additionally, we used the GRADE approach to assess the certainty of evidence. Results: A total of 14 studies involving 1,062 participants were included. The meta-analysis showed that, compared with non-DASH diets, the DASH diet significantly reduced WC (MD = −2.33 cm, 95% CI: −3.10 to −1.57), systolic BP (MD = −5.52 mmHg, 95% CI: −6.83 to −4.21), diastolic BP (MD = −3.93 mmHg, 95% CI: −4.76 to −3.10), TG (MD = −16.57 mg/dL, 95% CI: −23.53 to −9.61), HDL-C (MD = 1.44 mg/dL, 95% CI: 0.20 to 2.68), and HOMA-IR levels (MD = −0.71, 95% CI: −1.10 to −0.31). However, no significant difference was observed in FBG (MD = −0.91 mg/dL, 95% CI: −4.51 to 2.68). The GRADE approach for assessing certainty of evidence indicated that, with the exception of FBG and HDL-C where the certainty of evidence was low, the overall certainty of evidence for the remaining outcome measures was rated as moderate quality. Conclusion: The DASH diet appears to have a positive effect on components of MetS and can be considered an effective dietary intervention for MetS patients. Systematic review registration: CRD420251060235.
- Open Access
- 10 April 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 71, 102582
Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
- 10 April 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 71, 102582
Open AccessEfficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
- Open Access
- 31 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 63, 102189
Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial
- 31 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 63, 102189
Open AccessAntiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial
- Open Access
- 1 June 2021
- Published by Elsevier in Integrative Medicine Research
- Vol. 10 (2) , 100665
The efficacy and safety of traditional Chinese medicines, modified Radix Fici Simplicissimae, combined with Western medicines amongst patients infected with the 2019 novel coronavirus (SARS-CoV-2) in tropical tourist area, China
- 1 June 2021
- Published by Elsevier in Integrative Medicine Research
- Vol. 10 (2) , 100665
Open AccessThe efficacy and safety of traditional Chinese medicines, modified Radix Fici Simplicissimae, combined with Western medicines amongst patients infected with the 2019 novel coronavirus (SARS-CoV-2) in tropical tourist area, China
- Open Access
- 9 November 2019
- Published by Springer Nature in BMC Medical Genetics
- Vol. 20 (1) , 1-7
Cascade screening for familial hypercholesterolemia-identification of the C308Y mutation in multiple family members and relatives for the first time in mainland China
Background: Familial hypercholesterolemia (FH), an autosomal dominant genetic disorder, is underdiagnosed and undertreated. The majority of FH cases are caused by low density lipoprotein receptor (LDL-R) gene mutations. The C308Y mutation in LDL-R results in approximately 70% loss of LDL-R activity, leading to the elevation of low density lipoprotein-cholesterol (LDL-C) and an increased risk of premature coronary heart disease (CHD). The aim of this study was to identify FH cases by cascade screening in family members and relatives of a 37-year old male with premature CHD and hypercholesterolemia. Methods: Clinical exam, blood lipid profiling and genomic DNA sequencing of all exons of LDL-R were performed for the proband and his 14 family members and relatives. FH diagnosis was carried out using the Dutch Lipid Clinic Network (DLCN) criteria. Results: Lipid profiling showed that 9 individuals, including the proband, had hypercholesterolemia. All these 9 subjects had a G > A substitution at nucleotide 986 in exon 7 resulting in the C308Y mutation as determined by DNA sequencing, and all those carrying the mutation were diagnosed as having definite FH under the DLCN criteria. However, most (7/9) did not have suggestive clinical manifestations of CHD. Conclusions: The C308Y mutation was discovered in multiple family members and relatives for the first time in mainland China. Cascade screening is key for the confirmatory diagnosis of FH. Our hypothesis that the C308Y is a common variant in the population of Southern China origin warrants further validation by screening for the C308Y mutation in a large population.
- 9 November 2019
- Published by Springer Nature in BMC Medical Genetics
- Vol. 20 (1) , 1-7
Open AccessCascade screening for familial hypercholesterolemia-identification of the C308Y mutation in multiple family members and relatives for the first time in mainland China
Background: Familial hypercholesterolemia (FH), an autosomal dominant genetic disorder, is underdiagnosed and undertreated. The majority of FH cases are caused by low density lipoprotein receptor (LDL-R) gene mutations. The C308Y mutation in LDL-R results in approximately 70% loss of LDL-R activity, leading to the elevation of low density lipoprotein-cholesterol (LDL-C) and an increased risk of premature coronary heart disease (CHD). The aim of this study was to identify FH cases by cascade screening in family members and relatives of a 37-year old male with premature CHD and hypercholesterolemia. Methods: Clinical exam, blood lipid profiling and genomic DNA sequencing of all exons of LDL-R were performed for the proband and his 14 family members and relatives. FH diagnosis was carried out using the Dutch Lipid Clinic Network (DLCN) criteria. Results: Lipid profiling showed that 9 individuals, including the proband, had hypercholesterolemia. All these 9 subjects had a G > A substitution at nucleotide 986 in exon 7 resulting in the C308Y mutation as determined by DNA sequencing, and all those carrying the mutation were diagnosed as having definite FH under the DLCN criteria. However, most (7/9) did not have suggestive clinical manifestations of CHD. Conclusions: The C308Y mutation was discovered in multiple family members and relatives for the first time in mainland China. Cascade screening is key for the confirmatory diagnosis of FH. Our hypothesis that the C308Y is a common variant in the population of Southern China origin warrants further validation by screening for the C308Y mutation in a large population.
- Open Access
- 1 June 2018
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 17 (1) , 131
Association of Achilles tendon thickness and LDL-cholesterol levels in patients with hypercholesterolemia
Achilles tendons are the most common sites of tendon xanthomas that are commonly caused by disturbance of lipid metabolism. Achilles tendon thickening is the early characteristic of Achilles tendon xanthomas. The relationship between Achilles tendon thickness (ATT) and LDL-C levels, and risk factors of ATT in patients with hypercholesterolemia, have thus far been poorly documented. A total of 205 individuals, aged 18-75 years, were enrolled from March 2014 to March 2015. According to the LDL-C levels and the “Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults”, all subjects were divided into 3 groups: normal group (LDL-C < 3.37 mmol/L, n = 51); borderline LDL-C group (3.37 mmol/L ≤ LDL-C ≤ 4.12 mmol/L, n = 50); and hypercholesterolemia group (LDL ≥ 4.14 mmol/L, n = 104). ATT was measured using a standardized digital radiography method and the results were compared among the 3 groups. The correlation between ATT and serum LDL-C levels was analyzed by Pearson’s correlation, and the risk factors of ATT were determined by the logistic regression model. ATT in borderline LDL-C group was 8.24 ± 1.73 mm, markedly higher than 6.05 ± 0.28 mm of normal group (P < 0.05). ATT in hypercholesterolemia group was 9.42 ± 3.63 mm which was significantly higher than that of normal group (P < 0.005) and that of borderline LDL-C group (P < 0.05). There was a positive correlation between the serum LDL-C levels and ATT (r = 0.346, P < 0.001). The serum LDL-C level was a risk factor (OR = 1.871, 95% CI: 1.067-3.280) while the levels of HDL-C (OR = 0.099, 95% CI: 0.017-0.573) and Apo AI (OR = 0.035, 95% CI: 0.003-0.412) were protective factors of ATT. ATT might serve as a valuable auxiliary diagnostic index for hypercholesterolemia and used for the assessment and management of cardiovascular disease.
- 1 June 2018
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 17 (1) , 131
Open AccessAssociation of Achilles tendon thickness and LDL-cholesterol levels in patients with hypercholesterolemia
Achilles tendons are the most common sites of tendon xanthomas that are commonly caused by disturbance of lipid metabolism. Achilles tendon thickening is the early characteristic of Achilles tendon xanthomas. The relationship between Achilles tendon thickness (ATT) and LDL-C levels, and risk factors of ATT in patients with hypercholesterolemia, have thus far been poorly documented. A total of 205 individuals, aged 18-75 years, were enrolled from March 2014 to March 2015. According to the LDL-C levels and the “Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults”, all subjects were divided into 3 groups: normal group (LDL-C < 3.37 mmol/L, n = 51); borderline LDL-C group (3.37 mmol/L ≤ LDL-C ≤ 4.12 mmol/L, n = 50); and hypercholesterolemia group (LDL ≥ 4.14 mmol/L, n = 104). ATT was measured using a standardized digital radiography method and the results were compared among the 3 groups. The correlation between ATT and serum LDL-C levels was analyzed by Pearson’s correlation, and the risk factors of ATT were determined by the logistic regression model. ATT in borderline LDL-C group was 8.24 ± 1.73 mm, markedly higher than 6.05 ± 0.28 mm of normal group (P < 0.05). ATT in hypercholesterolemia group was 9.42 ± 3.63 mm which was significantly higher than that of normal group (P < 0.005) and that of borderline LDL-C group (P < 0.05). There was a positive correlation between the serum LDL-C levels and ATT (r = 0.346, P < 0.001). The serum LDL-C level was a risk factor (OR = 1.871, 95% CI: 1.067-3.280) while the levels of HDL-C (OR = 0.099, 95% CI: 0.017-0.573) and Apo AI (OR = 0.035, 95% CI: 0.003-0.412) were protective factors of ATT. ATT might serve as a valuable auxiliary diagnostic index for hypercholesterolemia and used for the assessment and management of cardiovascular disease.